DHCR7 is a potential pan cancer biomarker for prognosis and immunotherapy
Author:
Wu Xianghua1, Gong Qinyuan2, Xu Xiaoliang3, Wang Li1, Zhang Xuzhao2, Yu Teng2, Zhu Gesheng1, Zheng Weiwei4, Lin Dan1, Wu Zhaoxing2
Affiliation:
1. The First People's Hospital of Yuhang District 2. Zhejiang University 3. Bengbu Medical College 4. The First Affiliated Hospital of USTC, University of Science and Technology of China
Abstract
Abstract
Background
7-dehydrocholesterol reductase (DHCR7) is a key enzyme involving the final step of cholesterol synthesis pathway. Abnormalities in the DHCR7 gene can lead to a variety of diseases, such as Smith-Lemli-Opitz syndrome. However, the relationship between DHCR7 and oncogenesis remain unclear.
Methods
We used several bioinformatic databases which the original data from the TCGA and GEO database. Briefly, the gene of DHCR7 expression were explored by the Oncomine, TIMER and GEPIA databases. The effect of DHCR7 on prognosis was analyzed via Kaplan-Meier plotter and GEPIA database. The TISIDB database was used to determine the relationship between DHCR7 expression and pan-cancer stages and the DHCR7 expression in different immune and molecular subtypes of human cancers. The correlations between DHCR7 expression and immune checkpoints (ICP), tumor mutational burden (TMB), microsatellite instability (MSI), mutant-allele tumor heterogeneity (MATH), neoantigens and infiltrating immune cells of human cancers and urogenital cancers were analyzed through the SangerBox database (http://vip.sangerbox.com/login.html). The genomic alterations of DHCR7 were analyzed by the c-BioPortal database. The differential expression of DHCR7 in urogenital cancers with different clinical characteristics was analyzed with the UALCAN database. The DHCR7 co-expression genes in BLCA was analyzed through the Linked Omics database. And the association between DHCR7 and related genes and markers of immune cells were analyzed by TIMER database.
Results
The results indicated that DHCR7 was highly expressed in most cancers, except in Cholangio carcinoma, Pheochromocytoma and Paraganglioma. Aberrantly expressed DHCR7 was associated with the poor prognosis, advanced tumor stage and metastasis in most tumor types. Additionally, significant strong correlations between DHCR7 expression and tumor immune-infiltrated cells (TILs), ICP, TMB, MSI, MATH and neoantigens showed in most human cancers, and marker genes of TILs were significantly related to DHCR7 expression in BLCA, KIRC and PRAD. DHCR7 co-expression networks mostly participated in the regulation of immune response regulating signaling pathway, leukocyte differentiation and angiogenesis.
Conclusion
Through pan-cancer analysis, DHCR7 may serve as a potential prognostic and immunological pan-cancer biomarker, especially in urological tumors.
Publisher
Research Square Platform LLC
Reference23 articles.
1. 1. Kim JH, Lee JN, Paik YK: Cholesterol biosynthesis from lanosterol. A concerted role for Sp1 and NF-Y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol reductase gene expression. J Biol Chem 2001, 276(21):18153–18160. 2. 2. Xiao J, Li W, Zheng X, Qi L, Wang H, Zhang C, Wan X, Zheng Y, Zhong R, Zhou X et al: Targeting 7-Dehydrocholesterol Reductase Integrates Cholesterol Metabolism and IRF3 Activation to Eliminate Infection. Immunity 2020, 52(1):109–122 e106. 3. 3. Waye JS, Nakamura LM, Eng B, Hunnisett L, Chitayat D, Costa T, Nowaczyk MJ: Smith-Lemli-Opitz syndrome: carrier frequency and spectrum of DHCR7 mutations in Canada. J Med Genet 2002, 39(6):E31. 4. 4. Zou J, Liu S, Long J, Yan B: High DHCR7 Expression Predicts Poor Prognosis for Cervical Cancer. Comput Math Methods Med 2022, 2022:8383885. 5. 5. Chen Y, Yan W, Yang K, Qian Y, Chen Y, Wang R, Zhu J, He Y, Wu H, Zhang G et al: Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer. J Exp Clin Cancer Res 2023, 42(1):36.
|
|